Previously, we and others demonstrated that targeting of BCR-controlled integrin-mediated adhesion underlies the clinical efficacy of BCR-signalosome inhibitors in CLL, MCL, and WM9–13. Here, BCR is linked to B-cell chronic lymphocytic leukemia.